Anavex Life Sciences Corp (AVXL)

[TempePhil]

Doc328, what do you think of this?
Lilly (March 2021) regarding their Alz P2 trial PRed

"Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. "

Where iADRS is is a composite tool that combines scores from the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and ADCS-iADL.

Now (9/2022) Biogen reports

"Lecanemab treatment....compared with placebo at 18 months by 27%."

Both of these trials are 18months, one reports 27% and the other 32% slowing of decline.
Just very curious that these separate trials and drugs came up with such a close
cog outcome, whether they used the same cog tests or not. Both subscribe to the aBeta theory.

I wonder are we are seeing the current limit of addressing Alz via the aBeta theory?
And of course addressing Alz upstream is where Anavex is at.

So we know, fairly well, where the competition is at, for the large field of BP that follows the aBeta theory. ...And then your post about what A2-73 needs to beat.